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Case 22-2019: A 65-Year-Old Woman with Myopathy
To the Editor: The case reported by Freeman 
et al. (July 18 issue)1 contains conclusions that 
may perpetuate misconceptions. The patient had 
acute rhabdomyolysis and necrotizing autoim-
mune myositis, but the connection with statins is 
unlikely.
In this patient, myopathy started 2 weeks af-
ter coryza and cough; this suggests a preceding 
viral infection, which is a more likely trigger of 
necrotizing autoimmune myositis2 than atorva-
statin, which had been initiated 6 months pre-
viously. Statins can rarely lead to acute myotox-
icity, but the contention that they induce 
anti-HMGCR (3-hydroxy-3-methylglutaryl coen-
zyme A reductase)–mediated autoimmunity is un-
substantiated and disputed.3 HMGCR is normally 
expressed in regenerating rather than necrotic 
fibers, and there is no evidence that it induces 
muscle-fiber necrosis or triggers autoimmunity, 
especially since HMGCR is a ubiquitous cyto-
plasmic antigen that is not accessible to anti-
HMGCR antibodies.4 HMGCR is expressed in 
normal myotubes, but anti-HMGCR IgG does 
not induce myotubular necrosis5 and does not 
explain pathogenicity.4 Most important, anti-
HMGCR autoantibodies are not statin-specific 
because they are most frequently seen in pa-
tients with paraneoplastic, viral, or other forms 
of necrotizing autoimmune myositis who have 
not received statins.6
In the few patients in whom necrotizing auto-
immune myositis does develop after receipt of 
statins for years, the association is more of a 
chance phenomenon, considering that necrotiz-
ing autoimmune myositis is now the most com-
mon inflammatory myopathy2,4 and that 25% of 
Americans older than 40 years of age take 
statins. The authors’ conclusions could deprive 
the patient, as well as others with a similar pre-
sentation, of a helpful drug.
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To the Editor: We would like to expand on the 
discussion by Freeman et al. on statin-associated 
autoimmune myopathy with autoantibodies 
against HMGCR in a patient who had been pre-
scribed a statin medication. First, we would note 
that this disease may also be associated with a 
dietary source of statins, such as red yeast rice or 
oyster mushrooms.1 Second, since at least 25% of 
patients with anti-HMGCR–associated autoim-
mune myopathy have no known exposure to 
statins,2 testing for anti-HMGCR autoantibodies 
may be considered in other patients with myopa-
thy. This includes adults and children with clini-
cal presentations that are consistent with genetic 
muscle disease but no known genetic defect; 
some of these patients have anti-HMGCR–associ-
ated autoimmune myopathy that responds to 
treatment.3 Third, reinitiation of statins is con-
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traindicated in patients with statin-associated 
autoimmune myopathy. However, the use of pro-
protein convertase subtilisin–kexin type 9 (PCSK9) 
inhibitors appears to be safe in this patient pop-
ulation and may be considered in patients with 
clinically significant cardiovascular risk factors.4
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The discussants reply: Dalakas raises an im-
portant point about the relationship between 
statin use and necrotizing autoimmune myopa-
thy. There is considerable epidemiologic evidence 
of an association between statin use and necro-
tizing autoimmune myopathy; however, data to 
establish statins as causal agents of the illness 
are lacking. In a large series involving 1947 pa-
tients with suspected myopathy who were evalu-
ated at the Johns Hopkins Myositis Center, 104 
(5.3%) were positive for anti-HMGCR autoanti-
bodies.1 Of these 104 patients, 75% had a history 
of statin use. Widespread use of statins, as seen 
in the United States, can lead to ascertainment 
bias, linking a rare myopathy with a commonly 
used drug class. Nevertheless, in the Johns Hop-
kins cohort, there was a strong association be-
tween antibodies and statin use. However, 25% 
of the patients with anti-HMGCR autoantibodies 
did not have a history of statin use; thus, necro-
tizing autoimmune myopathy can occur in the 
absence of statin exposure. As Dalakas suggests, 
anti-HMGCR autoantibodies may not necessarily 
be pathogenic, but they could be biomarkers of 
the immune-mediated process. Although viral 
illness is a potential trigger, we did not find 
compelling literature linking viral illness with 
anti-HMGCR autoantibodies. Although the dura-
tion of statin use before anti-HMGCR myopathy 
is variable, 2 or more years of exposure is fre-
quently reported. Thus, the time course in this pa-
tient is consistent with a statin-associated event.2,3 
We agree that Koch’s postulates for causality are 
not satisfied with regard to the role of statins or 
HMGCR autoantibodies in causing necrotizing 
autoimmune myopathy; until there is stronger 
evidence, it may be better to view the condition 
as statin-associated rather than statin-induced. 
We do not agree, however, with rechallenging pa-
tients with statins; this perspective was support-
ed in a recent review article stating that all five 
patients who were rechallenged had adverse ef-
fects.4 In our opinion, rechallenging a patient 
with a statin would require conclusive proof that 
a statin was not implicated in the disorder. Given 
the very refractory nature of necrotizing autoim-
mune myopathy, we think alternative cholesterol-
lowering therapy with the use of PCSK9 antibod-
ies or ezetimibe should be the recommended 
treatment for a patient after the development of a 
statin-associated anti-HMGCR myopathy.
We thank Pinal-Fernandez and Mammen for 
their comments. These letters raise important 
issues in understanding this rare immune-medi-
ated myopathy.
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